RanBP5, also known as Importin-9 (IPO9), is a protein that is part of the Ran-binding protein family and functions within the nucleus-cytoplasmic transport system. This system is essential for the directional transport of a variety of molecules, including proteins and RNAs, across the nuclear envelope. RanBP5 is particularly implicated in the nuclear import of proteins possessing a nuclear localization signal (NLS).The transport process hinges on the small GTPase Ran, which exists in a GTP-bound state in the nucleus and a GDP-bound state in the cytoplasm. RanBP5 acts as an adaptor that can bind to import substrates and facilitate their interaction with the nuclear transport receptor Importin-β. This complex then docks at the nuclear pore complex (NPC) and translocates into the nucleus. Upon entry into the nucleus, the high concentration of Ran-GTP induces a conformational change in RanBP5, leading to the release of the cargo.
RanBP5 is also involved in the nuclear export of proteins and RNAs by binding to Exportin-1 (CRM1) in a Ran-GTP-dependent manner, forming a trimeric complex that allows the passage of export cargos out of the nucleus. It also plays a role in the regulation of spindle assembly during mitosis and may be involved in cellular processes such as cell cycle control, differentiation, and signaling.Aberrant function or expression of RanBP5 has been implicated in various diseases, including cancer. It may contribute to the mislocalization of tumor suppressors or oncogenes, leading to altered cell proliferation and survival.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
This compound is a tyrosine kinase inhibitor, but paradoxically, it could lead to compensatory upregulation of ABL1 activity in non-targeted pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Another tyrosine kinase inhibitor that could potentially cause feedback enhancement of ABL1 in untargeted pathways. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Similar to other tyrosine kinase inhibitors, could induce upregulation of ABL1 through compensatory mechanisms. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
By inhibiting certain kinases, this compound might lead to a compensatory activation of ABL1. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
A flavonoid that may influence kinase signaling, potentially leading to indirect enhancement of ABL1. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
As a kinase modulator, EGCG could influence pathways that lead to the activation of ABL1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
May modulate kinase activity, potentially affecting ABL1 signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
While a PI3K inhibitor, it could indirectly lead to the activation of ABL1 through cross-talk between signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK, which may alter signaling cascades in a way that compensates with increased ABL1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This p38 MAPK inhibitor might enhance ABL1 activity through feedback loops in MAPK signaling. | ||||||